German healthcare firm Fresenius SE & Co. KGaA (FSNUF.PK,FSNPF.PK) Tuesday reported a higher fourth-quarter profit, as sales climbed, helped by growth in all of its business segments. Meanwhile, the group's publicly-listed unit Fresenius Medical Care AG & Co. KGaA (FMS) posted a decline in quarterly profit that reflected higher operating expenses, despite a rise in revenues. Both the firms have proposed higher dividend.
For the fourth quarter, Fresenius SE posted attributable net income of 241 million euros or 1.34 euros per share, higher than 205 million euros or 1.24 euros per share in the prior year. Excluding certain items, adjusted earnings were 1.42 euros per share, and it was 1.24 euros per share last year.
Quarterly sales grew to 5.19 billion euros from 4.39 billion euros a year earlier.
For the full year 2012, net income attributable to Fresenius SE increased to 926 million euros or 5.29 euros per share from 690 million euros or 4.18 euros per share in the previous year.
Excluding items, adjusted earnings were 5.36 euro per share, while the firm had posted 4.67 euro per share last year. Earnings before interest, tax, depreciation and amortization, or EBITDA, a key earnings measure, increased to 3.85 billion euros from 3.24 billion euros in the preceding year.
Annual sales of Fresenius SE grew 18 percent to 19.29 billion euros. Revenues were up 13 percent on a constant currency basis.
Division-wise, revenues of Kabi, a provider of generic drugs and infusion therapies, were 4.54 billion euros, up 15 percent from last year. Hospital operator Helios' sales climbed 20 percent to 3.20 billion euros. Sales of Vamed, which is engaged in international projects and services for hospitals, rose 15 percent to 846 million euros.
Ulf Mark Schneider, CEO of Fresenius SE said, "We saw strong organic growth, double-digit earnings increases and significant acquisitions in all our business segments."
Looking ahead to full-year 2013, the company expects adjusted earnings growth in the order of 7 percent to 12 percent. Revenues are expected to grow by 7 percent to 10 percent, at constant currency. It expects to reach 2014 Group net income target of more than 1 billion euros, one year ahead of its plan.
Fresenius SE also said its board will propose a dividend of 1.10 euro per share, up 16 percent from the prior year.
The group's publicly-listed medical care unit, Fresenius Medical Care, which focuses on dialysis care, reported fourth-quarter net income attributable to shareholders of $257.11 million or $0.84 per share, lower than $310.44 million or $1.02 per share in the prior year.
Excluding charges, totaling $71 million, net income attributable to shareholders was $327 million, an increase of 5 percent from last year and earnings per share were $1.07. On average, six analysts polled by Thomson Reuters expected earnings of $0.51 per share for the quarter. Analysts' estimates typically exclude special items.
Total net revenues of Fresenius Medical Care grew 13.5 percent to $3.71 billion. Analysts estimated revenues of $3.63 billion for the quarter.
For full year 2013, Fresenius Medical Care expects net income attributable to shareholders to be in the range of $1.1 billion to $1.2 billion. Excluding the investment gain, earnings is expected to grow between 5 and 15 percent. Revenues are anticipated to increase more than $14.6 billion.
Fresenius Medical Care will also propose a dividend of 0.75 euros per share, an increase of 9 percent from the prior year.
Fresenius SE shares are currently trading at 91.76 euros, up 0.84 percent, on Frankfurt's Xetra.
Fresenius Medical Care ended on Monday at $33.58 on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.